Loading
Hormone therapy of the kind used in prostate cancer shrank or controlled tumours in most patients with androgen receptor-positive salivary duct carcinoma, a treatment with far less toxicity than chemotherapy.
Prospective phase 2 study of 36 patients with androgen receptor-positive locally advanced or metastatic salivary gland carcinoma (predominantly salivary duct carcinoma) treated with leuprorelin and bicalutamide.
Objective response was 41.7 percent with a clinical benefit rate of 75 percent, median progression-free survival 8.8 months and median overall survival 30.5 months, and toxicity was mild.
Androgen receptor testing and androgen deprivation therapy are now standard options for salivary duct carcinoma, often before chemotherapy in slowly progressing disease.